Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4 Grant or award Director acquired 3,460 shares (grant or award)
  2. 4 Grant or award Director acquired 3,460 shares (grant or award)
  3. 4 Grant or award Director acquired 6,920 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Open-market sale 10% owner sold 52,616 shares at an average $22.23 ($1,169,868)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Grant or award Head of Regulatory acquired 10,000 shares (grant or award)
  11. 4 Grant or award Head of Quality acquired 20,000 shares (grant or award)
  12. 4 Derivatives Options or other derivatives
  13. 4 Open-market sale 10% owner sold 37,277 shares at an average $23.57 ($878,600)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Open-market sale VP, Clinical Trial Operations sold 19,800 shares at $24.70 ($489,060)
  16. 4 Open-market sale Head of Quality sold 515 shares at $23.73 ($12,221)
  17. 4 Open-market sale Head of Regulatory sold 935 shares at $23.73 ($22,188)
  18. 4 Open-market sale Chief Financial Officer sold 1,297 shares at $23.73 ($30,778)
  19. 4 Open-market sale General Counsel sold 328 shares at $23.73 ($7,783)
  20. 4 Open-market sale VP, Pharmaceutical Development sold 3,265 shares at $23.73 ($77,478)

Page 8 of 10 · 190 filings